Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8393398 | 0.92 | EPHX1 (0.49) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL8391372 | 0.92 | EPHX1 (0.53) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL21482089 | 0.91 | EPHX1 (0.39) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL8391889 | 0.90 | EPHX1 (0.56) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL8396101 | 0.90 | EPHX1 (0.56) | EPHX1HRH4HRH3SIGMAR1NPC1 | |
| SCHEMBL8396346 | 0.88 | EPHX1 (0.52) | EPHX1HRH4HRH3SIGMAR1TDP1 | |
| SCHEMBL8395535 | 0.82 | HRH4 (0.45) | EPHX1HRH4HRH3L3MBTL1TPSAB1 | |
| SCHEMBL12648114 | 0.82 | EPHX1 (0.55) | EPHX1TDP1TSHR | |
| SCHEMBL22281965 | 0.80 | GPR119 (0.41) | EPHX1HRH4HRH3SIGMAR1BCHE | |
| SCHEMBL8393248 | 0.80 | EPHX1 (0.48) | EPHX1HRH4HRH3SIGMAR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2020154447-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2011109037-A1 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | ENANTA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | EPHX1 4841/4885HRH4 3245/4885HRH3 3363/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | EPHX1 4841/4885HRH4 3245/4885HRH3 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.